IFP Advisors’s Summit Therapeutics SMMT Stock Holding History

IFP Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$25.5K	Buy	1,508 +1,339	+792%	+$20K	﹤0.01%	2815
2026 Q2	$2.46K	Hold	169	–	–	﹤0.01%	4145
2026 Q1	$3.2K	Sell	169 -4,260	-96%	-$68.9K	﹤0.01%	3772
2025 Q4	$77.5K	Hold	4,429	–	–	﹤0.01%	1950
2025 Q3	$91.5K	Buy	4,429 +65	+1%	+$1.58K	﹤0.01%	1736
2025 Q2	$92.9K	Buy	4,364 +4,264	+4,264%	+$97.2K	﹤0.01%	1682
2025 Q1	$1.93K	Sell	100 -404	-80%	-$8.1K	﹤0.01%	3155
2024 Q4	$8.99K	Buy	504 +4	+0.8%	+$78	﹤0.01%	2567
2024 Q3	$11K	Buy	+500	New	+$6.99K	﹤0.01%	2386

Other funds holding SMMT

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Hohimer Wealth Management Seattle, Washington $1.03B AUM 25.45% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Griffin Asset Management New York $934M AUM 18.69% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

IFP Advisors's SMMT Position: Q3 2026 in Review

IFP Advisors increased its Summit Therapeutics (SMMT) stake by 792% in Q3 2026, buying an estimated $20K and bringing the position to 1,508 shares worth $25.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2815.

IFP Advisors first reported a position in SMMT in Q3 2024 and has held it in 9 quarters since. The position peaked at $92.9K in Q2 2025. 121 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

IFP Advisors held 1,508 shares of Summit Therapeutics worth $25.5K as of Q3 2026.
IFP Advisors bought 1,339 Summit Therapeutics shares in Q3 2026, an estimated $20K.
Summit Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #2815 holding.
IFP Advisors first reported a position in Summit Therapeutics in Q3 2024 and has held it in 9 quarters since.
IFP Advisors's Summit Therapeutics position peaked at $92.9K in Q2 2025.
121 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.